Printer Friendly

LIDAK PHARMACEUTICALS RECEIVES NOTICES OF ALLOWANCE ON TWO U.S. PATENTS FOR THE TREATMENT OF ARTHRITIS

 LIDAK PHARMACEUTICALS RECEIVES NOTICES OF ALLOWANCE
 ON TWO U.S. PATENTS FOR THE TREATMENT OF ARTHRITIS
 LA JOLLA, Calif., Nov. 4 /PRNewswire/ -- LIDAK Pharmaceuticals (NASDAQ: LDAKA) announced today that it has received notices of allowance on two U.S. patents relating to the use of LIDAKOL as a systemic treatment of arthritis and other inflammatory diseases. The new patents cover the use of LIDAKOL by injection or other means of introduction, including transmucus or transdermal penetration in the treatment of such diseases in humans and animals. LIDAK owns previously issued patents relating to the use of LIDAKOL as a topical treatment for viral and inflammatory diseases and as a systemic treatment of viral diseases.
 The current development of LIDAKOL is focused on the topical treatment of oral and genital herpes. Phase II human clinical trials on patients with oral herpes and genital herpes are scheduled to begin this month under an Investigational New Drug application filed with the U.S. Food and Drug Administration. Development work on other potential topical indications including therapeutic use in burn injuries, wound healing and fungal infections is in the preclinical stage. An ongoing goal of the company is to develop LIDAKOL as a potential systemic treatment of viral and inflammatory diseases including cytomegalovirus (CMV), influenza, HIV and arthritis.
 According to David H. Katz, LIDAK's president and chief executive officer, "The patent coverage for the systemic treatment of arthritis and other inflammatory diseases expands the potential long-term value of this drug to LIDAK. We are encouraged by our early studies in these new therapeutic areas and plan to continue investigating all potential systemic uses of LIDAK," said Katz.
 LIDAK Pharmaceuticals is developing pharmaceutical products for the health care industry. LIDAK is currently focusing its efforts on the commercialization of LIDAKOL as a treatment for herpes and other indications. Also, the company is developing its Large Multivalent Immunogen technology for potential new therapies against cancer and viral diseases. The company's longer-term projects include the development of proprietary technology for potential new therapeutic and diagnostic approaches to diabetes, cancer and AIDS.
 -0- 11/4/92
 /CONTACT: Michael H. Lorber, vice president and CFO of LIDAK Pharmaceuticals, 619-558-0364, or Cathleen Mayrose of Dewe Rogerson, 212-688-6840, for LIDAK Pharmaceuticals/
 (LDAKA) CO: LIDAK Pharmaceuticals ST: California IN: MTC SU:


CK-OS -- NY011 -- 2402 11/04/92 10:47 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 4, 1992
Words:388
Previous Article:STATEMENT BY CHRYSLER CHAIRMAN LEE A. IACOCCA ON THE PRESIDENTIAL ELECTION
Next Article:MOBIL TO BUILD TWO NEW PIPELINES AT ITS HOUSTON OLEFINS PLANT
Topics:


Related Articles
AMYLIN PHARMACEUTICALS INC. ANNOUNCES NOTICE OF PATENT ALLOWANCE
LIDAK RECEIVES PATENT FOR SYSTEMIC USES OF LIDAKOL
LIDAK RECEIVES EUROPEAN PATENT FOR LIDAKOL
LIDAK PHARMACEUTICALS RECEIVES EUROPEAN PATENT
LIDAK PHARMACEUTICALS RECEIVES EUROPEAN PATENT FOR CANCER IMMUNOTHERAPY TECHNOLOGY
LIDAK PHARMACEUTICALS RECEIVES EXPANDED PATENT COVERAGE ON TOPICAL LIDAKOL(TM) CREAM

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters